Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Patent
1988-06-30
1992-07-21
Doll, John
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
424 858, 424 8591, 435 691, 435 696, 435 7021, 4351722, 4351723, 43524027, 4352523, 4353201, 53038826, 935 15, 536 27, C07K 1528, C12N 510, C12N 520, C12P 2108
Patent
active
051324059
ABSTRACT:
Disclosed are a family of synthetic proteins having affinity for a preselected antigen. The proteins are characterized by one or more sequences
REFERENCES:
patent: 4474893 (1984-10-01), Reading
patent: 4642334 (1987-02-01), Zaffaroni et al.
patent: 4666837 (1987-05-01), Harford et al.
patent: 4704692 (1987-11-01), Ladner
patent: 4946778 (1990-08-01), Ladner et al.
Jones et al., "Replacing the Complementarity-Determining Regions in a Human Antibody With Those From a Mouse," Nature, 321:522-525, May 29, 1986.
Van Brunt (1986) Biotechnology, 4:277-283.
Wetzel et al. (1981) Gene, 16:63-71.
Cabilly et al. (1984) Proc. Natl. Acad. Sci. USA, 81:3273-3277.
Vogel (1987) Current Approaches of Immunotargeting In Immunoconjugates Antibody Conjugates in Radioimaging and Therapy of Cancer (C.-W. Vogel, ed.) N.Y., Oxford University Press, pp. 3-7.
Itakura et al. (1977) Science, 198:1056-1063.
Hochman et al., Biochemistry 12:1130-1138.
Schultz, P. G., Science 240:426-432 (1988).
Abstract A; Blue Sheets 5:S5 (Jul. 3, 1985).
Letter from Mr. Joseloff (NIH).
Abstract B (Jan. 27, 1986) SBIR Phase I.
SBIR (NIH) Phase II Grant Application (Dec. 13, 1985).
Brown et al. Cancer Res. 47:3577.
Gascoigne et al., PNAS (USA) 84:2936.
Tan et al., J. Immunol. 135:3564.
Takeda et al., Nature (London) 314:453.
Kabat et al., PNAS (USA) 75:2429.
Tonegawa et al., PNAS (USA) 74:3518.
Nishimura et al., Cancer Res. 47:999.
Morrison, Science (WDC) 229:1202.
Boulianne et al., Mol. Biol. Med. (ENG) 4:37.
Liu et al., Gene (Neth) 54:33.
Baer et al., Cell 43:705.
Corvalen et al. (1987) Cancer Immunol. Immunother. 24:133-137.
Corvalen and Smith (1987) Cancer Immunol. Immunother. 24:127-132.
Sun et al., (1987) Proc. Natl. Acad. Sci. USA 84:214-218.
Boulianne et al., (1984) Nature 312:543-646.
Haber and Novotny (1985) "The Antibody Combining Site" in Hybridoma Technology in the Bioscience and Medicine, Plenum Publishing Corp. pp. 57-76.
Haber (1983) Biochem. Pharmacol. 32:1967-1977.
Marx (1985) Science 229:455-456.
Kabat et al. (1979) Sequence of Immunoglobulin Chains.
NIH Publication No. 80-2008, pp. 1-107.
Morrison et al., (1984) Proc. Natl. Acad. Sci. USA 81:6851-6855.
Neuberger et al., (1984) Nature 312:604-608.
Rice and Baltimore (1982) Proc. Natl. Acad. Sci. USA, 79:7862-7865.
Rosemblatt and Haber (1978) Biochem. 17:3877-3882.
Erlich et al. (1980) Biochem. 19:4091-4096.
Inbar et al. (1972) Proc. Natl. Acad. Sci. USA 69:2659-2662.
Sharon and Givol (1976) Biochem. 15:1591-1594.
Huston et al. (1972) Biochem. 11:4256-4262.
Dammacco et al. (1972) J. Immunol. 109:565-569.
Sahagan et al. (1986) J. Immunol. 137:1066-1074.
"Genex makes a miniaturized monoclonal antibody", Newswatch, Monday, Oct. 20, 1986, p. 5.
Klausner (1986) Biotechnol. 4:1041-1043.
Huston James S.
Oppermann Hermann
Budens Robert D.
Creative BioMolecules, Inc.
Doll John
LandOfFree
Biosynthetic antibody binding sites does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Biosynthetic antibody binding sites, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Biosynthetic antibody binding sites will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-844349